Literature DB >> 2597200

Persistent intracellular binding of mitoxantrone in a human colon carcinoma cell line.

R A Roberts1, A E Cress, W S Dalton.   

Abstract

Incubation of human carcinoma cells with mitoxantrone resulted in an intracellular distribution of the drug into cytoplasmic, nuclear and cytoskeletal compartments occurring within 1 min of drug treatment. Incubation of the cells in drug-free medium resulted in an efflux of the drug such that 80% of the intracellular drug was eliminated from the cells by 72 hr. Approximately 20% of the initial intracellular drug concentration remained in the cells after the drug had been removed from the medium. The majority of the persistent intracellular drug was associated with soluble cytoplasmic proteins and fractions enriched in nucleic acid. Approximately 10% of the persistent drug binding was associated with cellular structures that had been depleted of soluble cytoplasmic protein and nucleic acid. During the persistent drug binding, the cells enlarged at least 2-fold as determined by microscopic examination. An increasing percentage of the cells was also observed to contain a DNA content consistent with a G2 cell cycle arrest. Taken together, these data suggest that the persistent intracellular binding of mitoxantrone results in a G2 cell cycle arrest and cellular damage.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2597200     DOI: 10.1016/0006-2952(89)90527-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Expression of cytokeratin confers multiple drug resistance.

Authors:  P A Bauman; W S Dalton; J M Anderson; A E Cress
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

2.  Localization and molecular interactions of mitoxantrone within living K562 cells as probed by confocal spectral imaging analysis.

Authors:  A Feofanov; S Sharonov; I Kudelina; F Fleury; I Nabiev
Journal:  Biophys J       Date:  1997-12       Impact factor: 4.033

3.  Quantitative confocal spectral imaging analysis of mitoxantrone within living K562 cells: intracellular accumulation and distribution of monomers, aggregates, naphtoquinoxaline metabolite, and drug-target complexes.

Authors:  A Feofanov; S Sharonov; F Fleury; I Kudelina; I Nabiev
Journal:  Biophys J       Date:  1997-12       Impact factor: 4.033

Review 4.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

5.  Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin.

Authors:  G R Fisher; L H Patterson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells.

Authors:  M E Fox; P J Smith
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 7.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.

Authors:  L H Patterson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.